The Aftermath of Tapering Tocilizumab After Achieving Treatment Target in Patients With Rheumatoid Arthritis: A Nationwide Cohort Study

The Aftermath of Tapering Tocilizumab After Achieving Treatment Target in Patients With Rheumatoid Arthritis: A Nationwide Cohort Study

BackgroundAlthough recent guidelines recommend that tapering of biologic disease-modifying anti-rheumatic drugs (bDMARDs) can be considered in patients with rheumatoid arthritis (RA), there has been little evidence supporting the strategy during the non-tumor necrosis factor inhibitor treatment. Thi...

Full description

Bibliographic Details
Main Authors:	Jun Won Park, Min Jung Kim, Hyoun-Ah Kim, Jin Hyun Kim, Eun Bong Lee, Kichul Shin
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-02-01
Series:	Frontiers in Medicine
Subjects:	rheumatoid arthritis tocilizumab dose tapering treat-to-target bDMARD therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2022.839206/full

Similar Items

Prediction Aided Tapering In rheumatoid arthritis patients treated with biOlogicals (PATIO): protocol for a randomized controlled trial
by: Marianne A. Messelink, et al.
Published: (2022-06-01)

Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative Review
by: Claudia Iannone, et al.
Published: (2023-02-01)

Compared efficacy of rituximab, abatacept, and tocilizumab in patients with rheumatoid arthritis refractory to methotrexate or TNF inhibitors agents: a systematic review and network meta-analysis
by: Alisson Pugliesi, et al.
Published: (2023-07-01)

Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis
by: Thomas Wilke, et al.
Published: (2017-08-01)

Impact of multimorbidity on the first ts/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry
by: Jerusalem Calvo-Gutiérrez, et al.
Published: (2024-02-01)

Biological treatment and exercise as an alternative to typical rheumatoid arthritis therapy: pathophysiology and effects
by: Artur Aghadi, et al.
Published: (2023-02-01)

The Use of Tocilizumab in Combination with Methotrexate in Indonesian Rheumatoid Arthritis Patients (PICTURE INA Study)
by: Bambang Setyohadi, et al.
Published: (2018-06-01)

Treat-To-Target and Treat-To-Budget in Rheumatoid Arthritis: Measuring the Value of Individual Therapeutic Interventions
by: José A. Sacristán, et al.
Published: (2019-10-01)

Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort studyResearch in context
by: Maxime Beydon, et al.
Published: (2023-12-01)

Using real-world data to dynamically predict flares during tapering of biological DMARDs in rheumatoid arthritis: development, validation, and potential impact of prediction-aided decisions
by: Matthijs S. van der Leeuw, et al.
Published: (2022-03-01)

Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry
by: Ju-Yang Jung, et al.
Published: (2023-09-01)

Difficult-to-treat rheumatoid arthritis in real clinical practice. Preliminary results
by: Elena A. Galushko, et al.
Published: (2022-06-01)

Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment
by: Krzysztof Bonek, et al.
Published: (2021-02-01)

Successful long-term remission through tapering tocilizumab infusions: a single-center prospective study
by: Chayma Ladhari, et al.
Published: (2020-02-01)

Analysis of survival rate and persistence predictors of baricitinib in real-world data from a large cohort of rheumatoid arthritis patients
by: Simone Parisi, et al.
Published: (2024-01-01)

RAPID EFFECT OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS
by: E Yu Panasyuk, et al.
Published: (2011-08-01)

The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis
by: Rieke Alten, et al.
Published: (2022-10-01)

Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis
by: Han Joo Baek, et al.
Published: (2019-07-01)

Tapering of biological treatment in autoinflammatory diseases: a scoping review
by: Tatjana Welzel, et al.
Published: (2022-08-01)

Prediction of ineffectiveness of biological drugs using machine learning and explainable AI methods: data from the Austrian Biological Registry BioReg
by: Dubravka Ukalovic, et al.
Published: (2024-02-01)

Stopping bDMARDs at the beginning of pregnancy is associated with disease flares and preterm delivery in women with rheumatoid arthritis
by: Maria Chiara Gerardi, et al.
Published: (2022-08-01)

Biological agents in monotherapy for the treatment of rheumatoid arthritis
by: Cem Gabay, et al.
Published: (2014-04-01)

Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician
by: Findeisen KE, et al.
Published: (2021-08-01)

IL-10 Induced by mTNF Crosslinking-Mediated Reverse Signaling in a Whole Blood Assay Is Predictive of Response to TNFi Therapy in Rheumatoid Arthritis
by: Marco Krasselt, et al.
Published: (2022-06-01)

The Role of M1/M2 Macrophage Polarization in Rheumatoid Arthritis Synovitis
by: Maurizio Cutolo, et al.
Published: (2022-05-01)

Defining the Optimal Strategies for Achieving Drug-Free Remission in Rheumatoid Arthritis: A Narrative Review
by: Hanna Gul, et al.
Published: (2021-12-01)

Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial
by: Matthijs S. van der Leeuw, et al.
Published: (2020-04-01)

Bone-sparing effects of tocilizumab in rheumatoid arthritis: a monocentric observational study
by: Suhel Gabriele Al Khayyat, et al.
Published: (2022-11-01)

Impact of access to treatment on patient‐reported outcomes among rheumatoid arthritis patients with tDMARDs and bDMARDS in two Latin‐American countries: A prospective observational study
by: Juan M. Reyes, et al.
Published: (2023-03-01)

PREDICTION OF TOCILIZUMAB AND RITUXIMAB EFFECTIVENESS IN RHEUMATOID ARTHRITIS
by: Volkava M. V.
Published: (2019-11-01)

Egyptian guidelines for the treatment of Rheumatoid Arthritis — 2022 update
by: Yasser El Miedany, et al.
Published: (2022-10-01)

Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series
by: Rossella Talotta, et al.
Published: (2018-06-01)

TOCILIZUMAB IMPACT ON BLOOD CHOLESTERINE TRANSPORT AND EARLY MANIFESTATION OF ATHEROSCLEROSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: T V Popkova, et al.
Published: (2012-05-01)

The efficacy and safety of short-term and low-dose IL-2 combined with tocilizumab to treat rheumatoid arthritis
by: Sheng-Xiao Zhang, et al.
Published: (2024-04-01)

Ultrasound-detected bone erosion is a relapse risk factor after discontinuation of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis whose ultrasound power Doppler synovitis activity and clinical disease activity are well controlled
by: Shin-ya Kawashiri, et al.
Published: (2017-05-01)

Impact of tocilizumab therapy on fatigue in patients with rheumatoid arthritis
by: Anna Sergeyevna Starkova, et al.
Published: (2012-06-01)

Effect of Dysmetabolisms and Comorbidities on the Efficacy and Safety of Biological Therapy in Chronic Inflammatory Joint Diseases
by: Laura Cometi, et al.
Published: (2020-05-01)

The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
by: Daniel H. Solomon, et al.
Published: (2021-01-01)

Exploring the Role of Interleukin-6 Receptor Inhibitor Tocilizumab in Patients with Active Rheumatoid Arthritis and Periodontal Disease
by: Codrina Ancuța, et al.
Published: (2021-02-01)

Patterns of Prednisone Use in Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine US Clinical Practice
by: Dimitrios A. Pappas, et al.
Published: (2019-06-01)